Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
08
12
2020
revised:
04
01
2021
accepted:
05
01
2021
pubmed:
5
2
2021
medline:
3
11
2021
entrez:
4
2
2021
Statut:
ppublish
Résumé
Ataluren is a compound that reads through premature stop codons and increases protein expression by increasing translation without modifying transcription or mRNA stability. We investigated the safety and efficacy of ataluren in children with nonsense variants causing Dravet Syndrome (DS) and CDKL5 Deficiency Syndrome (CDD). This single-center double-blind, placebo-controlled crossover trial randomized subjects to receive ataluren or placebo for 12 weeks (period 1), a 4-week washout, then another 12-week treatment (period 2). The primary outcome was ataluren's safety profile. The secondary outcome measures were (1) changes in convulsive and/or drop seizure frequency and (2) changes in minor seizure types during ataluren treatment compared to placebo. Exploratory objectives assessed changes in cognitive, motor, and behavioral function as well as quality of life during ataluren therapy. We enrolled seven subjects with DS and eight subjects with CDD. Three treatment-related adverse events (AE) occurred during the blinded phases. Two subjects withdrew due to AE. Ataluren was not effective in reducing seizure frequency or improving cognitive, motor, or behavioral function or quality of life in subjects with either DS or CDD due to nonsense variants. Limitations included a small sample size and 12-week treatment phase, possibly too short to identify a disease-modifying effect. There was no difference between ataluren and placebo; ataluren is not an effective therapy for seizures or other disorders in children with DS or CDD due to nonsense variants. There were no drug-related serious AE during the double-blind period, consistent with ataluren's favorable safety profile in larger studies. (Funded by Epilepsy Foundation, Dravet Syndrome Foundation, Finding A Cure for Seizures and Epilepsy and PTC Therapeutics, Inc.; ClinicalTrials.gov number, NCT02758626).
Identifiants
pubmed: 33538404
doi: 10.1002/acn3.51306
pmc: PMC7951093
doi:
Substances chimiques
Codon, Nonsense
0
Oxadiazoles
0
ataluren
K16AME9I3V
Banques de données
ClinicalTrials.gov
['NCT02758626']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
639-644Informations de copyright
© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Lancet. 2017 Sep 23;390(10101):1489-1498
pubmed: 28728956
Seizure. 2011 Dec;20(10):789-94
pubmed: 21868258
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2064-9
pubmed: 18272502
Pharmacogenet Genomics. 2013 Apr;23(4):236-41
pubmed: 23407051
Nature. 2007 May 3;447(7140):87-91
pubmed: 17450125
Epilepsy Behav. 2016 Nov;64(Pt A):69-74
pubmed: 27732919
J Clin Pharmacol. 2007 Apr;47(4):430-44
pubmed: 17389552
Clin Pharmacol Drug Dev. 2019 Feb;8(2):172-178
pubmed: 30629861
Epilepsia. 2011 Apr;52 Suppl 2:44-9
pubmed: 21463279
Pediatr Neurol. 2019 Aug;97:18-25
pubmed: 30928302
J Neurodev Disord. 2017 Jun 12;9:7
pubmed: 28616096
J Clin Pharm Ther. 1995 Aug;20(4):215-9
pubmed: 8557785
Adv Neurol. 2005;95:71-102
pubmed: 15508915
Methods Mol Biol. 2011;741:137-54
pubmed: 21594783
RNA. 2010 Sep;16(9):1832-47
pubmed: 20675403
Mol Syndromol. 2012 Apr;2(3-5):137-152
pubmed: 22670135
Epilepsy Res. 2011 Jun;95(1-2):86-93
pubmed: 21474289
Muscle Nerve. 2014 Oct;50(4):477-87
pubmed: 25042182